Search research articles
Contact Us
Filters
Showing results (11-20 of 148) with videos related to
Page
of 15
Sort By:
The Lancet. Rheumatology
|
February 1, 2021
Divergent effects of acute versus chronic glucocorticoids in COVID-19
Philip C Robinson, Eric Morand
Maturitas
|
June 2, 2014
Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities
Philip C Robinson, Simon Horsburgh
The Lancet. Rheumatology
|
June 14, 2022
Racial and ethnic differences in COVID-19 outcomes: a call to action
Philip C Robinson, Jinoos Yazdany
Expert Opinion on Pharmacotherapy
|
November 7, 2017
Lesinurad for the treatment of hyperuricaemia in people with gout
Philip C Robinson, Nicola Dalbeth
The Lancet. Rheumatology
|
April 28, 2021
Patients with gout: an under-recognised group at high risk of COVID-19
Nicola Dalbeth, Philip C Robinson
The Lancet. Diabetes & Endocrinology
|
July 4, 2015
Does midlife obesity really lower dementia risk?
Philip C Robinson, Tony R Merriman
Australian Prescriber
|
October 23, 2020
Management of autoimmune disease during the COVID-19 pandemic
Philip C Robinson, , Evan C Bursle, et al.
Rheumatic Diseases Clinics of North America
|
October 23, 2012
The genetics of ankylosing spondylitis and axial spondyloarthritis
Philip C Robinson, Matthew A Brown
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
August 7, 2010
Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals
Philip C Robinson, William J Taylor
The Journal of Rheumatology
|
August 2, 2021
The COVID-19 Pandemic and Rheumatology: Impact on Providing Care in Latin America and Around the World
Sebastian E Sattui, Philip C Robinson
Page
of 15
Search research articles
Search
Showing results (11-20 of 148) with videos related to
Sort By:
Page
of 15
The Lancet. Rheumatology
|
February 1, 2021
Divergent effects of acute versus chronic glucocorticoids in COVID-19
Philip C Robinson, Eric Morand
Maturitas
|
June 2, 2014
Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities
Philip C Robinson, Simon Horsburgh
The Lancet. Rheumatology
|
June 14, 2022
Racial and ethnic differences in COVID-19 outcomes: a call to action
Philip C Robinson, Jinoos Yazdany
Expert Opinion on Pharmacotherapy
|
November 7, 2017
Lesinurad for the treatment of hyperuricaemia in people with gout
Philip C Robinson, Nicola Dalbeth
The Lancet. Rheumatology
|
April 28, 2021
Patients with gout: an under-recognised group at high risk of COVID-19
Nicola Dalbeth, Philip C Robinson
The Lancet. Diabetes & Endocrinology
|
July 4, 2015
Does midlife obesity really lower dementia risk?
Philip C Robinson, Tony R Merriman
Australian Prescriber
|
October 23, 2020
Management of autoimmune disease during the COVID-19 pandemic
Philip C Robinson, , Evan C Bursle, et al.
Rheumatic Diseases Clinics of North America
|
October 23, 2012
The genetics of ankylosing spondylitis and axial spondyloarthritis
Philip C Robinson, Matthew A Brown
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
August 7, 2010
Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals
Philip C Robinson, William J Taylor
The Journal of Rheumatology
|
August 2, 2021
The COVID-19 Pandemic and Rheumatology: Impact on Providing Care in Latin America and Around the World
Sebastian E Sattui, Philip C Robinson
Page
of 15